Women With BRCA1 Germline Deleterious Mutation Clinical Trial
Official title:
Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)
BRCA1 carriers who are at high risk of developing either a relapse and/or a new cancer growth will be included. These patients will be followed up during 30 months (2,5 years) with mutated TP53 mutation detection or during 42 months (3,5 years) with mutated TP53 mutation detection and circulating tumor cells detection (CTC) performed at each hospital visit (for technical reason only patients included at Institut Curie will be proposed to participate to the CTC substudy).
n/a